Author(s): LIN Youen, LI Liwen, LIN Dongqun
Pages: 18-20
Year: 2009 Issue:  21
Journal: China Foreign Medical Treatment
Keyword:  Advanced esophageal cancer; Paclitaxel; Hydroxycamptothecin ;
Abstract: Objective To observe the clinical therapeutic effect and safety of Paclitaxel combined with Hydroxycamptothecin(HCPT) in treatment of advanced esophageal cancer. Methods 70 cases of advanced esophageal cancer patients were randomly divided into PH group and NP group. PH group was given treatment of Paclitaxel combined with HCPT, while the NP group was given treatment of NVB combined with DDP.The clinical therapeutic 47.1%, disease control rate of 73.5%;NP group had efficiency of 43.3%, disease control rate of 63.3%, there was no significant difference(P>0.05) 70.6%; NP group survival rate was 26.7%, mortality rate was 73.3%,there there were serious leukopenia and hair loss situation,the incidence was>90%,but the PH group Ⅲ～Ⅳ level incidence was significantly lower than the NP group(P<0.05);PH group the incidence and grade Ⅲ～Ⅳ incidence of joint muscle pain,nausea and vomiting were significantly lower than the control group(P<0.05).Conclusion Paclitaxel combined with HCPT in treatment of advanced esophageal cancer is effective,adverse reactions can be tolerated,and it is worth further clinical research and extension.